The Changing Landscape of Inflammation and Anaemia in CKD

Renal anaemia is being reframed around a single mechanism: the inflammation–IL-6–hepcidin–iron-restriction axis. This bench-to-bedside session links molecular biology to the clinic — from hepcidin and iron-restricted erythropoiesis, through IL-6 targeting (ziltivekimab, RESCUE and the anticipated ZEUS read-out), to HIF stabilisers in real-world practice after the 2026 KDIGO update. You'll gain a mechanistic framework that makes sense of today's fast-moving anaemia evidence and sharpens your treatment decisions across resource settings.